Novo Nordisk Cuts Ozempic Prices Sharply in India Amidst Generic Rivals
Novo Nordisk is set to sharply lower the price of its popular GLP-1 drug, Ozempic, in India. This decision comes as Indian drugmakers quickly launched cheaper generic versions of semaglutide right after the patent expired on March 21. The move marks a significant shift for the Danish company, as it prioritizes keeping sales volume in India's fast-growing, price-sensitive market over its usual high-price strategy.
Fierce Price Competition for Ozempic
Ozempic currently costs between ₹8,800 and ₹11,175 per month in India. Novo Nordisk is expected to reduce this price to roughly ₹5,000-₹6,000, a 30-50% cut. This new price is still higher than many generic versions. The price cut aims to combat Indian companies like Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences, which have already released their semaglutide drugs. For example, Dr. Reddy's Obeda costs ₹4,200 monthly, and Sun Pharma's weekly options range from ₹750 to ₹2,000. Eris Lifesciences and Natco Pharma offer even cheaper options, some as low as ₹1,290 a month. This intense rivalry shows how much cost matters in India, especially with high rates of diabetes and obesity.
The Growing Indian GLP-1 Market
The market for GLP-1 drugs in India is growing rapidly. It is expected to jump nearly five times from an estimated ₹1,000–₹1,200 crore in 2025 to around ₹4,500–₹5,000 crore by 2030. This growth is fueled by the increasing rates of type 2 diabetes and obesity in India, a country often called the 'diabetes capital of the world'. The market was valued at $110.55 million in 2024 and is forecast to grow at an annual rate of 34.3%. Generic drug entries after patent expiry are likely to speed up market adoption and cause prices to fall by 40-50% by FY27.
Comparing Valuations
Valuations show a clear difference between Novo Nordisk and its Indian rivals. Novo Nordisk's price-to-earnings (P/E) ratio over the last twelve months (TTM) is 9.94, 10.07, or 12.68. This is considerably lower than the healthcare sector average of 20.82. This might mean the market is already accounting for possible lower profits or different growth rates for Novo Nordisk worldwide. Indian companies have higher P/E ratios: Sun Pharmaceuticals at 38.33-39.42, Dr. Reddy's Laboratories at 17.8-19.61, Zydus Lifesciences at 17.95-19.17, and Eris Lifesciences from 39.50-65.62. The higher ratios for Indian firms, especially Eris, could indicate investor expectations for growth from generic sales or their strong market positions.
Risks Include Lower Profits and Brand Value
Cutting Ozempic's price in India presents risks for Novo Nordisk. The main worry is lower profit margins. A 30-50% price drop, while necessary to keep customers, significantly reduces the earnings from a key drug. This aggressive pricing, even to compete with generics, could harm Ozempic's premium image. When affordability is crucial, this change might make it harder for Novo Nordisk to charge high prices for its patented drugs later. India's regulatory bodies, like the National Pharmaceutical Pricing Authority (NPPA), and rules such as the Drug Price Control Order (DPCO), aim to keep drug prices accessible. While patented drugs aren't directly price-controlled, broader drug price rules mean companies must be cautious. The rapid launches of semaglutide generics by companies like Sun Pharma, Dr. Reddy's, Zydus, Natco, and Eris show a tough market where share can be quickly lost, possibly weakening the future pricing power of patent holders.